In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
List view / Grid view
Filter the results
Researchers have used a novel DNA-editing method to convert one base pair to another, increasing the lifespan of mice with progeria.
A new technique using CRISPR has been developed by researchers to identify programmed stem cells that mature into neuronal cells.
Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.
In October this year, Emmanuelle Charpentier and Jennifer Doudna, the two scientists who pioneered the revolutionary gene-editing technology CRISPR, were awarded the Nobel Prize in Chemistry. Here, Pushpanathan Muthuirulan discusses the potential for this technology and the importance of using it safely, ethically and responsibly.
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
Using a new CRISPR-Cas9 tagging strategy, researchers have developed a method that enables the imaging of hundreds of proteins in parallel.
Researchers have found bioengineering CHO cells using CRISPR-Cas9 can decrease the secretion of metabolic by-products that hinder growth.
In a new study, scientists identify some of the pitfalls when using CRISPR Cas9 to correct mutations in human embryos, such as the destruction of whole chromosomes.
Emmanuelle Charpentier and Jennifer Doudna have been given the 2020 Nobel Prize in Chemistry for their discovery and development of CRISPR-Cas9 genome editing.
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
Researchers used CRISPR gene-editing to develop a vaccine able to protect against the spread of the Leishmania major parasite which causes cutaneous leishmaniasis.
A novel CRISPR system that suppresses genes related to adeno-associated virus (AAV) antibody production has been developed to prevent immunity against the gene therapy.
A new CRISPR technology has been created to understand mutations based on cytosine to guanine base changes and minimise unintended "off-target" mutations.